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The	aryl	hydrocarbon	receptor	repressor	(AHRR)	is	a	bHLH/Per-ARNT-Sim	transcription	factor	located	in	a	
region	of	chromosome	5	(5p15.3)	that	has	been	proposed	to	contain	one	or	more	tumor	suppressor	genes.	We	
report	here	consistent	downregulation	of	AHRR	mRNA	in	human	malignant	tissue	from	different	anatomical	
origins,	including	colon,	breast,	lung,	stomach,	cervix,	and	ovary,	and	demonstrate	DNA	hypermethylation	as	
the	regulatory	mechanism	of	AHRR	gene	silencing.	Knockdown	of	AHRR	gene	expression	in	a	human	lung	can-
cer	cell	line	using	siRNA	significantly	enhanced	in	vitro	anchorage-dependent	and	-independent	cell	growth	as	
well	as	cell	growth	after	transplantation	into	immunocompromised	mice.	In	addition,	knockdown	of	AHRR	
in	non-clonable	normal	human	mammary	epithelial	cells	enabled	them	to	grow	in	an	anchorage-independent	
manner.	Further,	downregulation	of	AHRR	expression	in	the	human	lung	cancer	cell	line	conferred	resistance	
to	apoptotic	signals	and	enhanced	motility	and	invasion	in	vitro	and	angiogenic	potential	in	vivo.	Ectopic	
expression	of	AHRR	in	tumor	cells	resulted	in	diminished	anchorage-dependent	and	-independent	cell	growth	
and	reduced	angiogenic	potential.	These	results	therefore	demonstrate	that	AHRR	is	a	putative	new	tumor	
suppressor	gene	in	multiple	types	of	human	cancers.
Introduction
The aryl hydrocarbon receptor repressor (AHRR) is a newly dis-
covered member of the growing superfamily of basic helix-loop-
helix/Per-ARNT-Sim (bHLH/Per-ARNT-Sim) transcription factors, 
which includes the aryl hydrocarbon receptor (AHR) (1) and hypox-
ia inducible factor 1 (HIF1) (2), among others. AHRR represses the 
transcription activity of AHR by competing with this transcription 
factor for heterodimer formation with the AHR nuclear transloca-
tor (ARNT) (3) and subsequently binding to the xenobiotic response 
element (XRE) sequence (4), functioning as a naturally occurring 
dominant-negative factor. Furthermore, the expression of AHRR 
is induced by the AHR/ARNT heterodimer (5) through binding to 
XREs located in the 5′-flanking region of the AHRR gene. There-
fore, AHRR and AHR constitute a regulatory loop in which the het-
erodimer AHR/ARNT activates expression of the AHRR gene, while 
the expressed AHRR inhibits the function of AHR (4).
Proof of the role of AHR as a ligand-activated transcription fac-
tor that mediates a pleiotropic response to environmental con-
taminants, such as benzo[a]pyrene, 2,3,7,8-tetrachlorodibenzo-p-
dioxin, and tobacco smoke is extensive (6, 7). More importantly, 
data exist implicating AHR in the development of cancers from 
different anatomical origins (8–10). Compelling evidence of the 
tumorigenic potential of AHR comes from the fact that AHR-
overexpressing transgenic mice spontaneously develop tumors 
(8, 9), whereas AHR-knockout mice have increased resistance to 
carcinogens (11). In this context, as an AHR regulator, AHRR is 
potentially involved in a vast array of normal and pathological pro-
cesses ranging from xenobiotic response to tumor progression. In 
humans, AHRR maps to the short arm of chromosome 5 (5p15). 
This chromosomal region has been shown to be frequently deleted 
in a variety of tumor types, such as cervical and testicular germ 
tumors (12), colorectal cancer (13), early-stage ovarian tumors 
(14), bladder cancer (15), esophageal cancer (16), and lung tumors 
(17). Based on these loss-of-heterozygosity (LOH) studies, 5p15 
has been often proposed as a chromosomal locus which likely 
harbors at least one tumor suppressor gene. The role of AHRR in 
carcinogenesis has not been extensively explored. Overexpression 
of AHRR in the breast cancer cell line MCF-7 results in growth 
inhibition (18) and genetic polymorphisms in AHRR are related 
to susceptibility to advanced endometriosis (19). Here we provide 
clinical, genetic, and functional evidence from in vitro and in vivo 
experiments supporting a critical role of AHRR as a putative tumor 
suppressor gene in several types of human cancer.
Results
AHRR is downregulated in tumor cells. Our results show a consistent 
downregulation of AHRR throughout all the tumor types assessed 
in this study, including colon, breast, lung, stomach, cervical, and 
ovarian, when compared with normal tissues of the same anatomi-
cal origin (Figure 1). In preliminary experiments lung, breast, stom-
ach, and colon primary tumors showed substantial downregula-
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tion of AHRR when compared with normal tissue from the same 
patient, adjacent to the tumor (Figure 1A). Interestingly, some 
of the hyperplastic or adenomatous nonmalignant colon polyps 
showed a smaller (up to 40%) downregulation of AHRR (Figure 1B), 
suggesting a direct relationship between levels of AHRR expression 
and degree of transformation in colon cancer. In a separate experi-
Figure 1
AHRR mRNA expression levels 
in tumors and normal controls as 
assessed by real-time PCR. (A) 
Significant downregulation in AHRR 
mRNA (between 30% and 90%) 
was observed in tumors from sev-
eral origins. Data are presented as a 
ratio of mRNA levels in tumor versus 
normal control. (B) Primary colon 
tumors showed a very strong down-
regulation of AHRR mRNA when 
compared with normal controls. 
Interestingly, nonmalignant colon 
polyps exhibited a more moderate 
downregulation of AHRR mRNA 
when compared with colon tumors. 
Statistically significant differences 
were achieved when comparing lev-
els of AHRR in normal tissue with 
levels in polyps. (C) AHRR expres-
sion levels in normal cervical tissue, 
cervical tumor cell lines, and primary 
cervical tumors. Strong downregula-
tion or complete ablation of AHRR 
mRNA was observed in 100% of cell 
lines and 80% of the primary tumors 
when compared with normal con-
trols. Little variation was observed 
in the levels of AHRR mRNA among 
the normal controls. (D) All ovarian 
tumor cell lines included in this study 
showed downregulation of AHRR 
mRNA levels when compared with 
normal ovarian cell lines. (E) Box-
and-whisker plot showing significant 
downregulation AHRR mRNA levels 
observed in lung tumors and normal 
tissues from the same patients. 
***P < 0.001.
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ment, we found that 80% of cervical primary tumors and 100% of 
cervical cell lines showed significant reduction or complete abro-
gation of AHRR when compared with normal tissue (Figure 1C). 
Similar results were obtained with 14 ovarian carcinoma cell lines 
examined, which showed a strong downregulation of AHRR when 
compared with immortalized nonmalignant ovarian cell lines (Fig-
ure 1D). Additional proof of downregulation of AHRR mRNA in 
cancer comes from comparison of 11 lung tumor samples and nor-
mal tissue from the same patients (Figure 1E). All tumor samples 
showed significant silencing of AHRR mRNA when compared with 
their normal counterparts. Overall, these results show a consistent 
downregulation of AHRR mRNA in tumors of different histologi-
cal origins (Supplemental data; supplemental material available 
online with this article; doi:10.1172/JCI30024DS1).
AHRR satisfies Knudson’s “2-hit” hypothesis. Because of the downreg-
ulated expression of the AHRR gene in tumors from different tissue 
origins, and the frequent LOH at the 5p15 chromosomal region 
(12), we reasoned that AHRR might be a potential tumor suppres-
sor gene. Knudson’s “two hits” hypothesis considers tumor sup-
pressor genes by their functional inactivation achieved by a com-
bination of LOH, hypermethylation of the gene’s promoter, and 
mutations in the gene’s coding region (20). Although, as expected 
from previous studies (12, 21), a number of polymorphisms and 
evidence for frequent LOH of this region was obtained in this study 
(Supplemental Table 2), no evidence of pathogenic mutations in 
the coding region of the AHRR gene was found, pointing to hyper-
methylation as a possible mechanism responsible for its steady 
downregulation in tumors. Promoter hypermethylation was found 
in over 78% of the tumors examined (Table 1 and Supplemental Fig-
ure 2), while no methylation was found in normal tissue. Remark-
ably, almost all ovarian, cervical, and colon tumors exhibited pro-
moter hypermethylation. The lowest hypermethylation rate (13%) 
was found in seminoma testicular tumors (it has been reported 
that seminomatous germ cell tumors rarely exhibit 
promoter hypermethylation; ref. 22). Interestingly, 
levels of promoter hypermethylation were closely cor-
related with cancer grade in cervical and esophageal 
specimens: low-grade precancerous lesions showed 
the lowest levels of promoter methylation (4.2% 
and 0%, respectively), higher levels were observed in 
high-grade lesions (41% and 28%, respectively), and 
virtually all established cervical tumors (95.5%) and 
52% of esophageal tumors were methylated. Further 
supporting evidence that hypermethylation is a main 
regulatory mechanism of AHRR silencing in tumors 
comes from experiments in which tumor cells are 
exposed to demethylating agents. Treatment of 
tumor cells with 5-aza-dC and/or trichostatin A sig-
nificantly reactivated AHRR expression (more than 
1.5-fold increase) in 71.5% of the tumor cell lines 
included in the experiment (Supplemental Table 3). 
These data thus show that epigenetic alterations (i.e., 
hypermethylation) are largely responsible for down-
regulation of AHRR in cancer cells. Analysis of the 5′ 
regulatory region of AHRR showed several binding 
motif sites were found in the same region affected by 
hypermethylation including AP-2, c–Est-1, and Elk-1 
(Supplemental Table 4). Especially interesting was a 
short sequence, located close to the star codon (–55 
to –41 bp from the start codon), which contained 
potential binding sites for several members of the bHLH family of 
transcription factors including AHR and HIF.
The collective data shown above strongly suggest that AHRR 
may function as a tumor suppressor gene in cancers from dif-
ferent tissue origins. It is assumed that the loss of tumor sup-
pressor gene function correlates with an aggressive tumorigenic 
phenotype (23). siRNA technology in combination with in vitro 
cell-based growth assays (such as anchorage-independent growth 
assay) has been recently recognized as a successful strategy for 
identification of new tumor suppressor genes (24). In this con-
text, and to better understand the functional relevance of AHRR 
as a tumor suppressor gene, we artificially suppressed its expres-
sion by siRNA technology in the lung tumor A549 and normal 
breast MCF10A cell lines (Supplemental Figure 3). Transfected 
cells were tested for a number of established hallmark traits of 
the tumorigenic phenotype such as growth and colony formation 
both in vivo and in vitro and resistance to apoptosis, migration, 
and angiogenic potential (25).
Silencing of AHRR enhances tumor growth in vitro and in vivo through 
deregulation in cell cycle control. The hallmark of all neoplastic devel-
opment is deregulated cell proliferation (25). Downregulation of 
AHRR resulted in enhanced cell growth potential (Figure 2A). After 
5 days of transfection, a difference of 4.3- and 2.6-fold in growth 
was observed between A549E and A549G/F, respectively. Cell cycle 
analysis on these cells showed that the cell number on G2/M phase 
of A549F/G was significantly higher than that of A549E (Figure 
2, B–D). Consistently, G0/G1 phase was significantly decreased in 
these cells. In addition, we determined that several prooncogenic 
factors were significantly elevated on A549G, including Ras, PKCa, 
and cyclin A, while tumor suppressor factors such as PTEN and 
Ku80 were downregulated (Table 2). Further strengthening these 
results, downregulation of AHRR enhanced the ability of A549F 
and A549G to form colonies on anchorage-independent clono-
Table 1
AHRR promoter hypermethylation in cancer
Tumor type No. studied Methylated (%) UM/M (%) M/M (%)
Normal testis 4 0 0 0
Testicular cancer 79 44.3 42.8 57.2
 Seminoma 15 13.3 50 50
 Nonseminoma 64 51.6 42.4 57.6
Normal cervix 44 0 0 0
Cervical cancer 66 95.5 81 19
 Cell lines 9 100 11.1 88.9
 Primary tumors 57 94.7 92.6 7.4
Precancer
 Low-grade 48 4.2 ND ND
 High-grade 39 41 ND ND
Normal ovary 2 0 0 0
Ovarian cancer 14 100 21.4 78.6
Prostate cancer 6 67 ND ND
Colon cancer 8 100 ND ND
Normal esophagus 8 0 ND ND
Low-grade dysplasia 8 0 ND ND
High-grade dysplasia 7 28 ND ND
Tumor 23 52 ND ND
M/M, only methylated allele present; UM/M, unmethylated and methylated alleles pres-
ent; ND, not done.
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Figure 2
Effects of siRNA-induced silencing of 
AHRR on growth. (A) On a time-course 
MTT assay, A549G (squares) grew 
4.3-fold and A549F (triangles) grew 
2.6-fold faster than the empty nonsi-
lenced A549 cells (circles, A549E; dia-
monds, A549SR). No differences were 
observed between A549E and A549SR. 
(B–D) Cells deficient in AHRR (A549F 
[C] and A549G [D]) showed a signifi-
cant shift in the number of cells towards 
S and G2/M phases as compared with 
the control A549E (B). Consistently, a 
reduction in the number of cells in G0/G1 
phase was observed in A549F/G. (E 
and F) Artificial downregulation of AHRR 
enhanced A549 (E) and MCF10A (F) col-
ony formation (60% and 300% increase 
in average colonies for A549F/G 
and A549E, respectively). MCF10A-F 
and MCF10A-G were able to clone in 
soft agar, while, as expected, MCF10A-E 
did not form colonies. All clonogenic 
assays were run in triplicate. (G and 
H) Comparison of the morphology of 
the colonies formed by A549E (G) 
and A549G (H). A549E grew in com-
pact spheroids with defined contours. 
A549G colonies showed irregular mor-
phology and cells detached and partially 
separated from the core of the colony. 
Original magnification, ×20. (I) In an in 
vivo experiment, A549 cells transfected 
with a siRNA for AHRR showed a sig-
nificant increase in xenograft tumor vol-
ume 8 weeks after injection when com-
pared with empty plasmid–transfected 
A549 cells (3-fold increase for A549F 
[squares] compared with A549E [trian-
gles] and 7-fold increase for A549G [dia-
monds] compared with A549E). n = 10 
animals/group. *P < 0.05; **P < 0.01; 
***P < 0.001.
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genic assays (162% and 306% over A549E, respectively) (Figure 2E). 
Of note, the enhanced clonogenic capability was accompanied by 
differences in the morphology of the colonies. A549E typically 
grew in solid spheroids with defined colony contours (Figure 2G), 
whereas some of the colonies formed by A549F/G showed irregu-
lar contours and cells detached from the main core of the colony 
(Figure 2H). To further explore the link between AHRR silencing 
and clonogenic potential, we artificially silenced AHRR in the 
immortalized nonmalignant breast epithelial cell line MCF10A. In 
agreement with a previous report (26), MCF10A-E failed to form 
colonies in soft agar (Figure 2F). In contrast, MCF10A-F/G were 
able to grow in colonies displaying similar morphology to the one 
observed in A549F/G.
Overall, the data described above clearly demonstrate a link 
between AHRR downregulation and tumor cell growth in vitro. 
To further address this finding in an in vivo model of tumorigen-
esis, we injected A549E/F/G cells into nude mice and followed the 
development of xenograft tumors over time. A549F- and A549G-
induced tumors showed a 3- and 7-fold increase in volume, when 
compared with tumors generated by A549E (Figure 2I). Smaller 
differences were found between A549E and A549F (3-fold increase). 
These data further suggest that downregulation of AHRR is a con-
tributing factor to enhanced tumorigenicity.
AHRR silencing protects against apoptosis and enhances angiogenic poten-
tial, migration, and invasion in tumor cells. In addition to growth deregu-
lation and clonal expansion, resistance to apoptosis (27), enhanced 
angiogenic potential (28), and motility (25) lie at the heart of all 
tumor development. Here we show that silencing of AHRR confers 
resistance to apoptosis induced by overnight exposure to various 
proapoptotic signals (Figure 3A). Proteomics expression profile of 
A549G cells showed a significant elevation of the antiapoptotic fac-
tor Bcl-x (Table 2), suggesting potential explanatory mechanisms. 
We also studied the angiogenic potential of transfected A549 
cells in vivo using DIVAA. An 8-fold increase in neovasculariza-
tion-related fluorescence was observed in A549G when compared 
with A549E (Figure 3B). Similarly, A549F exhibited higher angio-
genic potential (5-fold increase) compared with A549E. Although 
sprouting of capillaries from quiescent vasculature on the tumor is 
a prerequisite for metastasis (28), enhanced motility and invasive-
ness are also required. The morphological alterations observed in 
A549F/G in clonogenic assays (Figure 2, F and G) suggest loss of 
cell-cell contact within the colonies and possibly higher migratory 
potential. Additionally, A549F/G showed increased (7- and 4.5-fold 
increase, respectively) migratory potential over A549E (Figure 3C). 
Similar results were obtained when testing the invasive potential of 
A549-transfected cells. Silencing of AHRR correlated with increased 
invasion, as observed through Matrigel staining (Figure 3C). These 
results are consistent with upregulation of prometastatic factors 
such as vimentin or phosphorylated focal adhesion kinase (FAK) 
and loss of E-cadherin, which is associated with loss of cell-cell 
interactions and enhanced invasive phenotype, in cells with artifi-
cially silenced AHRR (Table 2).
Ectopic expression of AHRR opposes the effect of siRNA for AHRR. 
Overexpression of AHRR was achieved in a transient fashion in 
A549 lung adenocarcinoma cells (Supplemental Figure 3C). 
AHRR was initially described as a repressor of the AHR, and our 
hypothesis contemplates a suppressor activity of AHRR linked to 
the AHR tumorigenic potential. To confirm biological activity of 
the overexpressed AHRR, we measured levels of the AHR-induced 
cancer-related gene CYP1A1. As expected, transfection of AHR-
induced CYP1A1 expression and cotransfection of AHRR counter-
acted the effect of AHR on reducing the levels of CYP1A1 (Figure 
Table 2
Comparison of the protein expression levels between A549G and A549E
Protein name SwissProt ID Fold change Comments
Vimentin P08670 +33.07 Overexpression is associated with metastatic potential
HES-1 NF +6.67 Regulates Notch and potentially plays a role in tumorigenesis
LAP2 Q62733 +6.13 May play an important role in nuclear envelope reassembly at the end of mitosis and/or  
    anchoring of the nuclear lamina and interphase chromosomes to the nuclear envelope
TAO1 O88664 +4.66 Regulates MAPK pathway
Casein kinase II a/a′ P19139 +4.17 Related with transformed phenotype and survival of cancer cells
Stat6 P42226 +3.36 Mediates repression of immunosurveillance
Phosphospecific FAK  Q05397 +3.13 Enhances cell motility, invasion, and tumor progression
PKCα P17252 +1.8 Implicated in events leading to keratinocyte differentiation, epidermal tumor promotion, and  
    cutaneous inflammation
Cyclin A P20248 +1.5 Key cell cycle regulator, the expression of which is found to be elevated in a variety of tumors
PTEN O00633 –1.8 Tumor suppressor gene, the downregulation of which enhances migration
Stat1 A46159 –1.9 Mediates growth inhibitory signals and contributes to the host rejection of tumors
MCM5 P33992 –2.4 Enhances Stat1 transactivation function
Ku80 P13010 –2.7 Mediates inhibition of hepatocellular carcinoma development
PKB P31749 –2.96 Leads to downregulation of tumor suppressor gene p53
DAP kinase P53355 –3.65 Loss of expression links suppression of apoptosis to metastasis
E-cadherin P12830 –4.65 Loss of expression represents a key step in the acquisition of the invasive phenotype for  
    many tumors
Bcl-x Q07817 BL Potent antiapoptotic factor
Bip/GRP78 P11021 BL Highly induced in growing tumors
Ras P01112 BL Oncogene that promotes cell progression
BL, below the detection limit in A549 and present in A549G; NF, not found in SwissProt database. Only data generated from good-quality signals with fold 
changes >1.5 were considered.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 118   Number 2   February 2008 645
4A), therefore confirming biological activity of the overexpressed 
AHRR as a repressor of AHR. Interestingly, A549-AHRR showed 
reduced growth rate over 3 days compared with A549-empty, as 
assessed by Electric Cell-Substrate Impedance Sensing (Figure 4B). 
Consistently, AHRR transfer resulted in inhibition of anchorage-
independent growth in clonogenic assays (Figure 4C). Colonies 
were morphologically similar and reached the same size (Figure 
4B), although significantly fewer colonies were found in A549-
AHRR samples. Also, using a modified tube formation assay in 
which PAE-GFP were cocultured (in separate Matrigel compart-
ments) with transfected A549 cells (Figure 4D), we demonstrated 
reduced tube formation after exposure to A549-AHRR compared 
with cells exposed to A549-empty, showing that overexpression of 
AHRR reduced the angiogenic potential of A549.
Discussion
Tumor formation arises as a consequence of the acquisition of 
unique cellular capabilities, which involve, among others, deregu-
lation of cell proliferation, resistance to apoptosis, enhanced cell 
motility, augmented angiogenic potential, and anomalies in cell-
cell interaction and the microenvironment, resulting in invasion 
and metastasis (25). Over the last several years, we have learned that 
this process is regulated by a relatively small subset of genes that 
act by either enhancing (oncogenes) or diminishing (tumor sup-
pressor genes) the final malignant outcome (29). Finding tumor 
suppressor genes is challenging, and although approaches based 
on analysis of LOH have been proven to be successful (29), we now 
know that multiple lines of evidence, including functional impli-
cations, are needed to confirm the identification of newly defined 
tumor suppressor genes (30). Here we provide clinical, genetic, and 
functional evidence supporting the hypothesis that silencing of 
the AHRR occurs in tumors from different tissue origins and that 
this mute expression results in an aggressive tumorigenic pheno-
type, thus suggesting that AHRR plays an important role in sup-
pressing tumor formation in humans.
In this study we demonstrate downregulation of AHRR through-
out all the tumor types assessed, including colon, breast, lung, 
stomach, cervical, and ovarian, when compared with normal tis-
sues of the same origin. Functional inactivation of tumor suppres-
sor genes is achieved by a combination of LOH, hypermethylation 
of the gene’s promoter, and mutations (20, 31). We have found 
high rates of LOH (together with several new polymorphisms) and 
hypermethylation in the promoter region of the AHRR gene in cer-
vical, testicular, and ovarian tumors. The majority of tumors, par-
ticularly ovarian cancer and testicular germ cell tumors, exhibited 
only methylated alleles, which can result from LOH of one allele 
and methylation of the other or methylation of both alleles. The 
first mechanism may certainly account for a proportion of cases, 
since 5p15 LOH is a common event in cervical cancer and testicu-
lar germ cell tumors (12, 21, 32–34). These data, together with the 
reactivation of AHRR expression after exposure to demethylating 
agents, are consistent with Knudson’s 2-hit hypothesis (20, 31) 
and indicate that LOH and hypermethylation constitute the main 
mechanism for the silencing of AHRR in tumors. Inactivation of 
tumor suppressor genes can represent an early event and a prereq-
uisite for clonal expansion. In support of this idea we, have found 
Figure 3
Effects of siRNA-induced silencing of AHRR. (A) A549E (black bars), 
A549F (white bars), and A549G (gray bars) were incubated in serum-
free media (R0) or the appropriate media containing α-Fas or MK886. In 
all experiments (n = 3), A549F/G showed enhanced resistant to proapop-
totic signals when compared with A549E. (B) DIVAA analysis showed 
that A549F and A549G have enhanced angiogenic potential when 
compared with A549E, and this effect was more prominent for A549G 
than for A549F (n = 8). (C) Silencing of AHRR (A549F/G) enhances the 
migratory (black bars) and invasive (white bars) potential of the A549 
tumor cell line (n = 6). Detail photos of the porous membranes used to 
determine migratory potential of A549E and A549G are also shown. 
Original magnification, ×10. *P < 0.05; **P < 0.01; ***P < 0.001.
research article
646	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 118   Number 2   February 2008
a direct relationship between hypermethylation of the AHRR pro-
moter region and tumor grade in cervical and esophageal cancer. 
Further supporting this idea, a small set of colon polyps (which 
we can consider as a naturally occurring example of premalignant 
lesions) showed intermediate downregulation of AHRR compared 
with colon tissues from healthy patients and frank colon tumors. 
This leads us to postulate that a reduced dosage of AHRR in the 
polyps, rather than its absolute absence, may contribute to cancer 
susceptibility in initial stages of the carcinogenic process.
Hypermethylation in the neighborhood of the start codon has 
been shown to suppress gene expression in tumor cells by either 
interfering with RNA polymerase II initiation or transcription fac-
tor binding (35). This region is therefore more likely to contain 
binding sequences for transcription factors relevant in AHRR regu-
lation in tumor cells. Several regions of the promoter of the AHRR 
gene have been shown to be potentially relevant for the regula-
tion of its expression (36, 37). We have found that the sequence 
contained between –55 bp and –41 bp from the start codon of 
the AHRR gene (which we have shown to be hypermethylated in 
tumors) is rich in potential binding sites for several members of the 
bHLH family of transcription factors, some of which are known 
to be upregulated in tumor cells (AHR, c-myc/MAX, and HIF-1). 
Upregulation of these transcription factors in cancer cells would 
potentially correlate with an increase in the levels of AHRR and an 
enhanced cancer suppressive action. However, hypermethylation 
of this promoter region and LOH prevent AHRR expression with 
Figure 4
Effect of ectopic expression of AHRR in A549. (A) Overexpression of AHRR partially blocked expression of AHR-induced genes such as CYP1A1 
(plasmid amounts expressed in μg). (B) Increased levels of AHRR in A549 resulted in reduced anchorage-dependent growth. The blue line 
represents A549-AHRR, and the red line represents A549-empty. Dotted lines denote standard deviation (n = 4). The maximum difference was 
reached 56 hours after inoculation of cells in the wells. (C) Ectopic expression of AHRR resulted in reduced anchorage-independent growth 
(adjacent images). Original magnification, ×10 (C); ×2 (D). (D) Representative images of tube formation assays using cocultures of A549-empty 
or A549-AHRR and PAE-GFP cells. A549-empty induced tube formation of PAE-GFP cells comparable to that of the internal positive control 
(10% FBS). Reduced tube formation was observed when PAE-GFP cells were cocultured with A549-AHRR. **P < 0.01; ***P < 0.001.
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concomitant loss of its repressor function and enhancement of the 
tumorigenic phenotype (Figure 5). Due to the significant length of 
the regulatory region on the AHRR gene, additional studies target-
ing this area are guaranteed to deepen our understanding of the 
role that methylation plays on AHRR expression in tumor cells.
Functional evidence of the tumor suppressive nature of AHRR 
arises from the study of the malignant phenotype in cells with 
artificially altered AHRR expression. Independent of the etiology 
of different tumors, deregulated cell proliferation together with 
suppressed apoptosis constitute a common platform upon which 
all neoplastic evolution occurs. Here we demonstrate that down-
regulation of AHRR enhances growth potential through deregu-
lation in cell cycle control and resistance to apoptosis (poten-
tially through deregulation of cyclin A and Bcl-x, respectively). 
AHRR inactivation is also linked to enhancement in anchorage-
independent growth of tumor cells. Artificial upregulation of 
AHRR results in impaired anchorage-dependent and -indepen-
dent growth. In agreement with these data, a recent report shows 
that overexpression of AHRR results in blockade of growth in the 
breast cancer cell line MCF-7 (18). Interestingly, partial silenc-
ing of AHRR in nontumoral MCF10A (which lack the ability of 
anchorage-independent growth; ref. 26) enables them to clone 
in soft agar, further supporting the important role of AHRR as a 
negative regulator of clonogenicity. Recently it has been shown 
that immortalized mouse mammary fibroblasts lacking AHR 
have impaired tumorigenicity in a subcutaneous mouse xeno-
graft model (38) and that its overexpression promotes progres-
sion through the cell cycle (39), 
triggering a malignant pheno-
type in vivo (8, 9). Tumors cells 
showing inactivation of the 
AHR negative regulator AHRR 
showed enhanced tumori-
genic potential, while AHRR 
activation resulted in dimin-
ished tumorigenic potential, 
in agreement with the logical 
hypothesis that inactivation 
of AHRR should lead to similar 
physiological consequences. 
The proteomic profile of cells 
silenced for AHRR shows that 
several prooncogenic fac-
tors such as Ras, HES-1, and 
casein kinase IIa and anti-
apoptotic factors such as Bcl-x 
are elevated, while tumor sup-
pressor molecules such as 
PTEN are diminished. This 
could explain the enhanced 
growth and apoptosis resis-
tance in these cells. These col-
lective data implicate AHRR 
as an important regulator of 
the overall tumor develop-
ment, the expression of which 
inversely correlated with cell 
growth and protected against 
apoptosis in cancer cells.
One of the essential capa-
bilities that enhances cancer cells’ tumorigenicity is their ability 
to migrate and become invasive. Here we show that silencing of 
AHRR tracks with increased motility and invasive potential in 
tumor cells and is accompanied by loss of E-cadherin, augmenta-
tion in vimentin, and phosphorylated FAK expression. Deregula-
tion of these proteins has been previously related to an increase 
in migratory potential and a more invasive phenotype in tumors 
(40–42). Consistent with our results, a recent report has shown 
that cells lacking AHR expression show downregulation of FAK 
and impaired migratory capabilities (38). The increased motility 
and the defined proteomic profile in AHRR-deficient cells could 
also account for the abnormal colony morphology observed in clo-
nogenic assays in which cells appeared to detach and migrate away 
from the main core of the colony. Tumor growth and metastasis 
rely on angiogenesis, the induction of new sprouting capillaries 
from quiescent vasculature (28). AHRR expression in tumor cells 
inversely correlates with their angiogenic potential. Tumor cells 
ectopically overexpressing AHRR showed lower angiogenic poten-
tial, while tumor cells in which AHRR expression was blocked 
showed high angiogenic potential. In summary, our data support 
that enhanced growth, clonal expansion, motility, and angiogenic 
potential, together with increased resistance to apoptotic signals, 
are cellular capabilities gained as a result of downregulation of 
AHRR expression and account for the xenograft growth potential 
of AHRR low-expressing cells in vivo.
The clinical, genetic, and functional data presented here implicate 
AHRR as a key regulator in the tumorigenic process whose down-
Figure 5
Working model of the tumor suppression mechanism for AHRR integrated in a gene regulation feedback 
loop with AHR. (A) In normal cells, activation of AHR causes induction of AHRR through XREs present in 
its promoter. AHRR acts as a negative regulator of AHR by competing for binding to ARNT and XREs pres-
ent in the promoter regulatory region of variety of genes. The balanced relationship between the positive 
and negative transactivation signals of AHR and AHRR results in cellular homeostasis. (B) In cancer cells, 
methylation of the AHRR promoter and LOH cause blockade of its expression despite the higher levels of 
AHR. Thus absence of AHRR eliminates competition for binding to ARNT and XREs, which results in an 
imbalance between positive and negative transactivation signals, thereby causing the induction of a battery 
of genes related to tumorigenesis and cancer progression.
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regulation (a consequence of methylation in tumor cells) induces 
pleiotropic effects, leading to tumor promotion and progression. 
Our data are consistent with the hypothesis that AHRR acts as a 
tumor suppressor gene in cancers from different tissue origins. The 
broad spectrum of signaling pathways regulated by AHRR renders 
this molecule an attractive biological target for developing new 
therapeutic intervention approaches against human cancers.
Methods
Normal tissue, tumor specimens, and cell lines. Colon specimens (normal 
controls and polyps) were obtained from standard colon pinch biopsies 
obtained during routine colonoscopy of patients without known predis-
position to colon cancer and from patients with hereditary nonpolyposis 
colorectal cancer under protocols approved by the Internal Review Boards 
of both the National Cancer Institute (NCI) and the National Naval Medi-
cal Center. Lung cancer and distal normal tissue was obtained from the 
University of Colorado Cancer Center Lung SPORE Tissue Bank. Tumors 
and corresponding normal tissue were snap frozen and stored in liquid 
nitrogen. Total RNA from pairs of individual human tumor and adjacent 
normal tissues (colon, lung, stomach, and breast) were obtained from 
Ambion. DNA isolated from 10 normal cervical smears and a total of 66 
tumors from cervix uteri (9 cell lines and 57 primary tumors) were utilized 
as described previously (43). All primary cervical cancers were squamous 
cell carcinoma of stages Ib to IV. Cervical cancer cell lines (HT-3, ME-180, 
HeLa, MS751, C-4I, C-33A, CaSki, SW756, and SiHa) were obtained from 
the ATCC. DNA obtained from 4 normal testes and 79 testicular germ cell 
tumors were used as previously described (44). All tumors (at least 60% 
tumor cellularity) were obtained after appropriate informed consent and 
approval of the protocols were obtained from the NIH IACUC. Total RNA 
from normal cervixes was purchased from 3 different sources (Ambion, 
Stratagene, and BioChain). DNA isolated from 2 normal ovarian cell lines 
(immortalized ovarian surface epithelium –IOSE 80 and IOSE 120; ref. 
45) and 14 ovarian carcinoma cell lines (A2780, AD10, OVCAR429, A224, 
CP70, OVT2[OF], CAOV3, 222, A547, A364, OVCAR3, UCI101, SKOV03, 
and UCI107) were also included in this study (46). All the ovarian cell lines 
were cultured as previously described (47). The bronchoalveolar carcinoma 
cell line A549, small lung cancer H417, and carcinoid H720 were obtained 
from ATCC. MCF10A was kindly provided by David Salomon (NCI) and 
maintained as previously described (26). The porcine endothelial cell PAE 
was obtained from Lena Claesson-Welsh (The Rudbeck Laboratory, Uppsala 
University, Uppsala, Sweden) through MTA agreement and subcultured as 
previously described (48).
RNA reverse transcription and real-time PCR. Reverse transcription was per-
formed using the SuperScript First-Strand Synthesis system (Invitrogen). 
PCR was performed using the ABI Prism 7900 Sequence Detection System 
(Applied Biosystems). Amplification was performed using 10 μM each of 
the following sense and antisense primers: AHRR sense, 5′-CTTAATG-
GCTTTGCTCTGGTCG-3′; AHRR antisense, 5′-TGCATTACATCCGTCT-
GATGGA-3′; 18S rRNA sense, 5′-ATGCTCTTAGCTGAGTGTCCCG-3′; 
18S rRNA antisense, 5′-ATTCCTAGCTGCGGTATCCAGG-3′ and SYBR 
Green Master Mix (Applied Biosystems).
DNA. The standard amplification program was according to the follow-
ing cycle scheme: initial denaturation of the samples at 50°C for 2 min, 
95°C for 10 min, 40 cycles of 95°C for 15 s, 60°C for 60 s. Fluorescence was 
measured in every cycle, and a defined single peak in the melting curve was 
obtained for all amplicons, thus confirming the specificity of the ampli-
fication. The final mRNA levels of the genes studied were normalized 
according to the 18S rRNA concentration of each sample.
Mutational analysis. Primer sets covering coding exons 2–11, and 5′ of 
exon 11 of AHRR gene were designed to amplify genomic DNA up to 240 
bp (Supplemental Table 1). Single-strand conformation polymorphism 
(SSCP) analysis was performed on PCR products generated from 30 cervi-
cal cancers in the presence of α[32P]dCTP and running 6% nondenaturing 
polyacrylamide gels containing 10% glycerol. Purified PCR products were 
sequenced to identify mutations.
Promoter methylation analysis by methylation-specific PCR. A CpG island 
(1,222 bp) spanning intron 1/exon 2/intron 2 of the AHRR gene was identi-
fied using GrailEXP Grail Experimental Gene Discovery Suite (http://grail.
lsd.ornl.gov/grailexp/). Two sets of primers for amplification of methylated 
and unmethylated DNA were designed by standard methods and were as 
follows: AHRR-M-F3, 5′-GTACGTGTATTTTTTCGGCG-3′; AHRR-M-R3, 
5′-CCGATAACTCCTCGATACGA-3′ ;  AHRR-U-F3, 5′-GTATGT-
GTATTTTTTTGGTGG-3′ ;  AHRR-U-R3, 5′-CCCAATAACTCCT-
CAATACA-3′ (–208 to 27 bp); and AHRR-M-F2, 5′-TTCGTCGTTTTC-
GTTTTTGTC-3′; AHRR-M-R2, 5′-CGAACGAACCGAAACTAAACTC-3′; 
AHRR-U-F2, 5′-GGTGGTTTTGTTTGTGGAGTTT-3′; AHRR-U-R2, 
5′-AAAACTCATCCCTACACCCTCA-3′ (–333 to –178 bp). Genomic DNA 
was treated with sodium bisulfite as previously described (43). Placental 
DNA treated in vitro with SssI methyltransferase (New England Biolabs) 
and normal lymphocyte DNA treated similarly with sodium bisulfite were 
used as controls for methylated and unmethylated templates, respectively. 
PCR products obtained from standard reaction were run on 2% agarose 
gels and visualized after ethidium bromide staining.
5-Aza-2′ deoxycytidine and trichostatin treatment and analysis of gene expres-
sion. Tumor cell lines (cervical: C-41, CaSKi, C-33A, HT-3, siHA, SW756, 
MS751m, ME-180, HeLa; testicular: CL2102EP, 2CL-21218A; and lung: 
A549, H720, H417) were treated with demethylating agent 5-Aza-2′ 
deoxycytidine (Sigma-Aldrich) for 5 days at a concentration of 5 μM, 
HDAC-inhibiting agent trichostatin A (Sigma-Aldrich) at a final concen-
tration of 250 nM for the last 24 hours, or a combination of both. Total 
RNA isolated from treated and untreated cell lines and the total RNA 
and polyA+ RNA from normal cervix obtained from commercial sources 
were reverse transcribed using random primers and the ProSTAR first-
strand RT-PCR kit (Stratagene).
Analysis of transcription factor binding sites in the promoter region of the AHRR 
gene. The 155-bp region corresponding to –333 bp to 27 bp from the start 
codon of the AHRR gene was searched for transcription factor binding sites 
using MathInspector software (49) (Genomatix Software GmbH). Only 
sequences with core similarity of 1, matrix similarity greater than 0.9, and 
optimized matrix threshold greater than 0.8 were considered.
Construction of expression plasmids and generation of transfectants. The 
mammalian expression vector pSuper.neo (OligoEngine) was used for 
expression of an AHRR-specific siRNA in A549 and MCF10A cells. Two 
gene-specific inserts (5′-GAGCTTCTTCCAAGTCGTG-3′ and 5′-GGCT-
GCTGTTGGAGTCTCTT-3′) were cloned into the pSUPER.neo backbone, 
and the final plasmids were referred to as pSuper.neo-F and pSuper.neo-G, 
respectively. A control vector containing no insert (empty vector, referred 
to as pSuper.neo-E) or a plasmid containing a scramble sequence (referred 
to as pSuper.neo-sr) or wild-type untransfected cells served as nonsilencing 
controls. To assess the appropriateness of the nonsilencing controls, equal 
levels of AHRR mRNA were confirmed in A549 transfected with pSuper.
neo-sr (A549SR), untransfected cells (A549WT), and A549 transfected with 
the empty vector (A549E) (Supplemental Figure 1A). Similar growth and 
migratory rates among A549E, A549SR, and A549WT were also observed 
(Supplemental Figure 1, B and C). The complete open reading frame of 
the human AHRR gene was amplified by PCR, cloned into the pcDNA 
3.1 TOPO TA mammalian expression vector (Invitrogen), and transiently 
transfected into A549 cells (A549-AHRR). Control vector (pcDNA3.1) con-
taining no insert was used to generate negative control cells (A549-empty). 
The open reading frame of GFP was cloned into the pcDNA3.1 TOPO TA 
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backbone (pcDNA3.1-GFP). All vectors were sequenced in the forward and 
reverse directions to verify the insertion of the AHRR and GFP sequences 
and the lack of insert in the control plasmids. A549 and MCF10A cells 
were transfected with plasmids pSuper.neo-E, pSuper.neo-F, or pSuper.
neo-G using FuGENE6 (Invitrogen) and exposed to the appropriate media 
containing 800 μg/ml geneticin (Invitrogen). A549 was transiently trans-
fected with pAHRR and pcDNA3.1 using the AMAXA nucleofector system. 
Expression of AHRR in both siRNA stable transfectants and transient over-
expressors was assessed by real-time PCR (Supplemental Figure 3). PAE 
cells were transiently transfected with pcDNA3.1-GFP (PAE-GFP). Selec-
tion of expressing cells was achieved by flow cytometry cell sorting using 
FACScan and CellQuest software (Becton Dickinson).
Growth assays. Proliferation of cells stably transfected with siRNA for 
AHRR or the empty vector was assessed by MTT assay. The dye and solu-
bilization solutions (Promega Proliferation Assay) were added every day 
for 5 days to separate 96-well plates, and absorbance was measured at 
570 nm with a Spectra Rainbow (Tecan) plate reader. Growth potential 
of A549-AHRR was assessed by Electric Cell-Substrate Impedance Sensing 
(ECIS Model 9600; Applied Biophysics) (50). A549-AHRR and A549-empty 
cells were seeded in 8W10E+ plates in RPMI supplemented with 10% FBS 
(RPMI-10). Measurements were performed for 4 days at 15 kHz.
Cell cycle analysis. For DNA content analysis, 3 × 106 cells (A549E, A549F, 
and A549G) were fixed, permeabilized in 70% ethanol, and washed twice in 
PBS (pH 7.4). Cells were then resuspended in 1 ml of PBS containing 50 μg 
propidium iodide (Sigma-Aldrich) and 1,000 units of DNAse-free RNase 
(Sigma-Aldrich) and incubated for 30 min at 37°C. The samples were run 
on a FACScan using CellQuest software and analyzed using the Sync Wiz-
ard option of MODFIT LT 2.0 (Verity Software House Inc.).
Soft agar clonogenic assay. The anchorage-independent growth of A549E, 
A549F, A549G, A549-empty, and A549-AHRR cells was examined by soft 
agar clonogenic assay. Briefly, 5,000 cells were resuspended in 1.5 ml of the 
culture media containing 10% FBS and 0.3% agarose and plated in 6-well 
plates with 1.5 ml of pre-solidified culture media in 0.5% agar containing 
10% FBS. Plates were incubated at 37°C for 4 weeks, and colonies larger 
than 0.1 mm in diameter were counted. The same procedure was followed 
for MCF10A-E, MCF10A-F, and MCF10A-G seeding 20,000 cells per well.
Xenografts. A549 cells transfected with the AHRR siRNA plasmids or the 
empty vector were injected into the flanks of athymic (nude) mice (1 × 107 
cells/mouse). The mice (10 animals/cell line) were checked daily for tumor 
formation by palpation, and tumor volume was estimated by measuring 
its size in 3 dimensions twice a week. This experiment was conducted in 
a blind fashion under animal protocol approved by the Animal Care and 
Usage Committee of NCI–Frederick Cancer Research Center.
Apoptosis assay. Cells were suspended in RPMI-10, seeded in 96-well 
plates, and incubated overnight. Then the plates were washed with RPMI 
media and exposed to: serum-free RPMI, RPMI-10 and α-Fas (5 μg/ml; 
MBL International Co.), and RPMI-10 and 0.5 μM of MK886 (Sigma-
Aldrich). After overnight incubation, early apoptosis was determined as 
the production of caspase-3/7 products using the Apo-ONE Homogenous 
Caspase-3/7 Assay (Promega).
Migration assays. Chemotaxis was assayed in 8-μm pore, 96-well ChemoTx 
plates (Neuroprobe). Cells (5 × 105) were placed in the upper chambers 
and the lower wells were filled with RPMI-10. After a 4-hour migration 
period at 37°C, nonmigrating cells were wiped off the top surface of the 
membrane. Then the membranes were fixed and stained with Hema3 (Bio-
chemical Sciences Inc.), and the cells trapped in the pores of the membrane 
were counted. Eight repeats were performed per sample.
Tube formation assays. The same number of A549-empty or A549-AHRR 
cells were seeded in 96-well plates. After the cells completely attached, 
the cells were washed 3 times with serum-free RPMI. Then 50 μl of base-
ment membrane extract (Trevigen) was laid down in each well. PAE-GFP 
cells (15,000) were then added on top of the gelled BME, and images were 
acquired with a fluorescent microscope after 3.5 hours.
Directed in vivo angiogenesis assay. Quantitation of angiogenesis was done 
using directed in vivo angiogenesis assay (DIVAA) as previously described 
(51). Briefly, 10-mm-long surgical grade silicone tubes with only 1 open 
end (angioreactors) were filled with 20 μl of Matrigel alone or Matrigel con-
taining 10,000 cells. After the Matrigel solidified, the angioreactors were 
implanted into the dorsal flanks of anesthetized athymic nude mice (NCI 
colony). After 11 days, the mice were injected i.v. with 25 mg/ml FITC-dex-
tran (100 μl/mouse; Sigma-Aldrich) 10 min before removing angioreactors. 
Quantitation of neovascularization in the angioreactors was determined 
as the amount of fluorescence trapped in the implants and was measured 
in a SpectraFluor microplate reader (Tecan). This protocol was approved 
by the NIH IACUC.
Proteomic analysis. A549G and A549E cells (106 cells per assay) were sus-
pended in boiling lysis buffer (10 mM Tris–HCl [pH 7.4], 1 mM sodium 
orthovanadate, 1% SDS) and homogenized by sonication. The protein con-
tent of each lysate was quantified by the bicinchoninic acid assay (Pierce 
Biotechnology) and subsequently processed by the PowerBlot facility 
(Becton Dickinson) to measure the expression level of 280 different signal-
transducing proteins related to cell cycle regulation and proteins suscep-
tible of phosphorylation. The experiment was performed in triplicate.
Statistics. Comparisons between groups were made using the 2-tailed Stu-
dent’s t test and the Mann-Whitney U test. Plotted data were expressed as 
mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001 are significance values 
used in the figures.
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